Differing total mRNA expression shapes the molecular and clinical phenotype of cancer
By
Shaolong Cao,
Jennifer R. Wang,
Shuangxi Ji,
Peng Yang,
Jingxiao Chen,
Matthew D Montierth,
John Paul Shen,
Jaewon J. Lee,
Paola A. Guerrero,
Kaixian Yu,
Julie Livingstone,
Vinayak Bhandari,
Shawna M Hubert,
Najat C. Daw,
P. Andrew Futreal,
Eleni Efstathiou,
Bora Lim,
Andrea Viale,
Jianjun Zhang,
Anirban Maitra,
Scott Kopetz,
Peter Campbell,
Terrence P. Speed,
Paul C. Boutros,
Alfonso Urbanucci,
Hongtu Zhu,
Jonas Demeulemeester,
Peter Van Loo,
Wenyi Wang
Posted 02 Oct 2020
bioRxiv DOI: 10.1101/2020.09.30.306795
Cancers can vary greatly in their transcriptomes. In contrast to alterations in specific genes or pathways, the significance of differences in tumor cell total mRNA content is poorly understood. Studies using single-cell sequencing or model systems have suggested a role for total mRNA content in regulating cellular phenotypes. However, analytical challenges related to technical artifacts and cellular admixture have impeded examination of total mRNA expression at scale across cancers. To address this, we evaluated total mRNA expression using single cell sequencing, and developed a computational method for quantifying tumor-specific total mRNA expression (TmS) from bulk sequencing data. We systematically estimated TmS in 5,181 patients across 15 cancer types and observed close correlations with clinicopathologic characteristics and molecular features, where high TmS generally accompanies high-risk disease. At a pan-cancer level, high TmS is associated with increased risk of disease progression and death. Moreover, TmS captures tumor type-specific effects of somatic mutations, chromosomal instability, and hypoxia, as well as aspects of intratumor heterogeneity. Taken together, our results suggest that measuring total mRNA expression offers a broader perspective of tracking cancer transcriptomes, which has important clinical and biological implications. ### Competing Interest Statement A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A.M. is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work.
Download data
- Downloaded 339 times
- Download rankings, all-time:
- Site-wide: 68,144
- In genomics: 4,803
- Year to date:
- Site-wide: None
- Since beginning of last month:
- Site-wide: 26,787
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!